Background
In recent years, due to the rapid deve>☆♣ lopment of biotechnology, especially the wid→≥"e application of genetic
en$☆↑gineering technology, biological m↕¥edicine has gradually developed into an importan♦<↕¥t part of the
pharmaceutical industry. ∞→☆traditionalization
Compared with pharma♣γ€φceutical products, biologic♦β&✔ drugs usually have π₹
larger and more complex mo∑<σlecular structures, so they have✘¥ their own unique research and development,
pr∞≠&↓oduction and market en§↔≠£vironment. It also means ↓$that biologic drugs
Patent protection mechanism↑♠s and related
legal frameworks require morβ✔♥₽e complex and specifi∏© αc requirements.
The st₹★↕udy found that biotechnology"☆♣✔ patents accounted for about 5 percent <® of total patent filings between 2001
and 2020✘§↑♣. The vast majority of biotechnolog ↔≈←y patents are related to industrial a€>nd medical applications,
accounπ☆δting for analysis
More than 96% of the$∑< total profit. The United States leads the way'≥ in biotech patent
development (39% of total bπ'iotech patents in 2020), followed by the Europ"'ean Union (18%)
And fas±↕&λt-growing
China (10%).
In this context, the Global Biotec↑φ•∑h & Pharma Patent (China) Summit will be h€¶eld in Shanghai on Junφ"e 5-6. The
summit will bring together governmeΩ§§nt and industry associations, domestλ>ic and foreign medicine
Industry₩α¶♠
experts from companies, biotechs→φ, governments, associations, law firms, IP agen cies and others attended to ♥ &≠
discuss the opportunities and challenges in t☆ &•he new environment.
